Njagi has published extensively in the areas of HIV/ AIDS, infectious diseases, maternal and child health and immunology.

  1. Postpartum weight change among HIV-infected mothers by antiretroviral prophylaxis and infant feeding modality in a research setting. Cames C, Cournil A, de Vincenzi I, Gaillard P, Meda N, Luchters S, Nduati R, Naidu K, Newell ML, Read JS, Bork K; Kesho Bora Study Group. AIDS. 2014 Jan 2; 28(1):85-94.
  2. Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. Sartorius BK, Chersich MF, Mwaura M, Meda N, Temmerman M, Newell ML, Farley TM, Luchters S; Kesho Bora Study Group. BMC Infect Dis. 2013 Nov 6; 13:522.
  3. Evaluation of PIMA™® point of care technology for CD4 T cell enumeration in Kenya. Mwau M, Adungo F, Kadima S, Njagi E, Kirwaye C, Abubakr NS, Okubi LA, Waihenya M, Lusike J, Hungu J. PLoS One. 2013 Jun 25; 8(6):e67612.
  4. Relationship between mortality and feeding modality among children born to HIV-infected mothers in a research setting: the Kesho Bora study. Cournil A, De Vincenzi I, Gaillard P, Cames C, Fao P, Luchters S, Rollins N, Newell ML, Bork K, Read JS; Kesho Bora Study Group. AIDS. 2013 Jun 19; 27(10):1621-30.
  5. Infant feeding modes and determinants among HIV-1-infected African Women in the Kesho Bora Study. Bork K, Cames C, Cournil A, Musyoka F, Ayassou K, Naidu K, Mepham S, Gichuhi C, Read JS, Gaillard P, de Vincenzi I; Kesho Bora Study Group. J Acquir Immune Defic Syndr. 2013 Jan 1; 62(1):109-18.
  6. Maternal HIV-1 disease progression 18-24 months post-delivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. Kesho Bora Study Group. Clin Infect Dis. 2012 Aug; 55(3):449-60.
  7. Changes in sexual behaviour among HIV-infected women in west and east Africa in the first 24 months after delivery. Irungu E, Chersich MF, Sanon C, Chege R, Gaillard P, Temmerman M, Read JS, Luchters S; Kesho Bora Study Group. AIDS. 2012 May 15; 26(8):997-1007.
  8. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Kesho Bora Study Group, de Vincenzi I. Lancet Infect Dis. 2011 Mar; 11(3):171-80.
  9. Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges. Kesho Bora Study Group. Contemp Clin Trials. 2011 Jan; 32(1):74-85.
  10. Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. Viljoen J, Gampini S, Danaviah S, Valéa D, Pillay S, Kania D, Méda N, Newell ML, Van de Perre P, Rouet F; World Health Organization/ANRS 1289 Kesho Bora Study Group. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):290-8.
  11. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. Kesho Bora Study Group. J Acquir Immune Defic Syndr. 2010 Aug; 54(5):533-41.
  12. Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. Rouet F, Foulongne V, Viljoen J, Steegen K, Becquart P, Valéa D, Danaviah S, Segondy M, Verhofstede C, Van de Perre P; WHO/ANRS 1289 Kesho Bora Study Group. J Virol Methods. 2010 Feb; 163(2):253-7.
  13. Prevalence of cytomegalovirus antibodies in blood donors at the National Blood Transfusion Centre, Nairobi. Njeru DG, Mwanda WO, Kitonyi GW, Njagi EC. East Afr Med J. 2009 Dec; 86(12 Suppl):S58-61.
  14. Type 2 diabetes mellitus: clinical and aetiologic types, therapy and quality of glycaemic control of ambulatory patients. Otieno CF, Huho AN, Omonge EO, Amayo AA, Njagi E. East Afr Med J. 2008 Jan; 85(1):24-9.
  15. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, Rutherford J, Njagi E, Mwangi F, Rostron T, Onyango J, Oyugi J, MacDonald KS, Bwayo JJ, Plummer FA. Immunol Lett. 2001 Nov 1; 79(1-2):3-13.
  16. Resistance to HIV-1 infection among African sex workers is associated with global hyporesponsiveness in interleukin 4 production. Trivedi HN, Plummer FA, Anzala AO, Njagi E, Bwayo JJ, Ngugi EN, Embree JE, Hayglass KT. FASEB J. 2001 Aug;15(10):1795-7.
  17. CD8 (+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, Njagi E, Irungu E, Farah B, Oyugi J, Chakraborty R, MacDonald KS, Bwayo JJ, McMichael A, Rowland-Jones SL. J Clin Invest. 2001 May; 107(10):1303-10.
  18. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, Rostron T, Njagi E, Bwayo JJ, MacDonald KS, McMichael AJ, Plummer FA.
  19. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB, Oyugi J, Njagi E, Gaur LK, Brunham RC, Wade J, Luscher MA, Krausa P, Rowland-Jones S, Ngugi E, Bwayo JJ, Plummer FA. J Infect Dis. 2000 May; 181(5):1581-9. Epub 2000 May 8.
  20. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, Njagi E, MacDonald KS, Bwayo JJ, McMichael AJ, Rowland-Jones SL. J Immunol. 2000 Feb 1; 164(3):1602-11.
  21. Genetic diversity and mosaicism at the por locus of Neisseria gonorrhoeae. Fudyk TC, Maclean IW, Simonsen JN, Njagi EN, Kimani J, Brunham RC, Plummer FA. J Bacteriol. 1999 Sep; 181(18):5591-9.
  22. Naturally occurring IgG anti-HLA alloantibody does not correlate with HIV type 1 resistance in Nairobi prostitutes. Luscher MA, Choy G, Njagi E, Bwayo JJ, Anzala AO, Ndinya-Achola JO, Ball TB, Wade JA, Plummer FA, Barber BH, MacDonald KS. AIDS Res Hum Retroviruses. 1998 Jan 20; 14(2):109-15.
  23. HIV-1 and immunological changes during pregnancy: a comparison between HIV-1-seropositive and HIV-1-seronegative women in Nairobi, Kenya. Temmerman M, Nagelkerke N, Bwayo J, Chomba EN, Ndinya-Achola J, Piot P. AIDS. 1995 Sep; 9(9):1057-60.
  24. Mass antimicrobial treatment in pregnancy. A randomized, placebo-controlled trial in a population with high rates of sexually transmitted diseases. Temmerman M, Njagi E, Nagelkerke N, Ndinya-Achola J, Plummer FA, Meheus A. J Reprod Med. 1995 Mar;40(3):176-80.
  25. Detection of human immunodeficiency virus type 1 (HIV-1) in heel prick blood on filter paper from children born to HIV-1-seropositive mothers. Nyambi PN, Fransen K, De Beenhouwer H, Chomba EN, Temmerman M, Ndinya-Achola JO, Piot P, van der Groen G. J Clin Microbiol. 1994 Nov; 32(11):2858-60.
  26. Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Temmerman M, Chomba EN, Ndinya-Achola J, Plummer FA, Coppens M, Piot P. Obstet Gynecol. 1994 Apr;83(4):495-501.
  27. HIV-1 and reproductive health in Africa. Temmerman M, Chomba EN, Piot P. Int J Gynaecol Obstet. 1994 Feb; 44(2):107-12.